Icade Zukünftiges Wachstum
Future Kriterienprüfungen 3/6
Icade wird ein jährliches Gewinn- und Umsatzwachstum von 86.7% bzw. 1.6% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 94.6% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 5.6% betragen.
Wichtige Informationen
86.7%
Wachstumsrate der Gewinne
94.65%
EPS-Wachstumsrate
| REITs Gewinnwachstum | 11.5% |
| Wachstumsrate der Einnahmen | 1.6% |
| Zukünftige Eigenkapitalrendite | 5.60% |
| Analystenabdeckung | Good |
| Zuletzt aktualisiert | 06 May 2026 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
ICAD: Slower Healthcare Disposal And Halted Special Payouts Will Pressure Shares
Analysts have reduced their price target on Icade from €30 to €25, citing expectations that the healthcare business disposal could take longer and that special dividends are no longer assumed over the next three years. Analyst Commentary Bearish analysts are flagging a more cautious stance on Icade, with recent research pointing to timing and payout uncertainties that weigh on sentiment.ICAD: Slower Healthcare Disposal And Lost Special Dividends Will Pressure Shares
Analysts have trimmed their price target for Icade to €25 from €30, reflecting expectations that the planned disposal of the healthcare business may take longer and that special dividends are no longer assumed over the next three years. Analyst Commentary Bearish analysts have shifted to a more cautious stance on Icade, with the rating cut to Equal Weight from Overweight and the price target moved to €25 from €30.
ICAD: Slower Healthcare Disposal And Missing Special Dividends Will Shape Fair Outlook
Narrative Update The analyst price target for Icade has been trimmed to €21.35 from €21.54. This reflects a more cautious stance from analysts after recent downgrades and expectations that healthcare asset disposals and potential special dividends may take longer to play out.
ICAD: Slower Healthcare Exit And Reset Distributions Will Support Future Repricing
Analysts have trimmed their fair value estimate for Icade to about €29.91 from €31.29, echoing recent price target cuts, such as the move from €30 to €25, as they factor in a longer timeline for healthcare asset disposals and the absence of expected special dividends. Analyst Commentary The recent research updates on Icade point to a more cautious stance as analysts reassess how quickly the group can execute on its healthcare disposals and how generous future shareholder returns might be.ICAD: Slower Healthcare Disposals And Lost Special Dividends Will Shape Fairly Valued Outlook
Analysts have modestly trimmed their fair value estimate for Icade from €22.03 to about €21.54. This reflects updated views on slower progress on healthcare disposals, a higher required discount rate and the removal of assumed special dividends after recent downgrades and price target cuts on the stock.ICAD: Higher Office Risk Premium Will Set Stage For Future Repricing
Analysts have reduced their fair value estimate for Icade from about €36.67 to about €31.29, reflecting a higher assumed discount rate and lower profit margin expectations following recent rating cuts and a lower €18 Street price target. Analyst Commentary Recent rating actions on Icade have leaned cautious, with cuts to both recommendations and price targets that feed into the lower fair value estimate.ICAD: Office Risk Repricing And Downgrades Will Shape Fairly Valued Outlook
Analysts have trimmed their fair value estimate for Icade from €23.33 to €22.03. This reflects a slightly higher discount rate, a modestly lower profit margin outlook and recent downgrades that cite a higher perceived equity risk premium in offices.ICAD: Office Risk Repricing And Downgrades Will Shape Future Share Performance
Analysts have trimmed their fair value estimate for Icade from about €23.46 to roughly €23.33, citing slightly higher required returns, more cautious assumptions on revenue growth and profit margins, and recent Street downgrades, including a cut in one price target from €25 to €18. Analyst Commentary Bullish Takeaways Bullish analysts may see the recent pullback in fair value and price targets as already reflecting higher equity risk premiums in offices, which can limit further downside if execution on existing projects is steady.ICAD: Office Downgrades And Higher Risk Premium Will Pressure Shares
Analysts have trimmed their price expectations for Icade to around €14.60, reflecting recent rating downgrades and a higher equity risk premium for office assets. This has been incorporated into updated assumptions for revenue growth, profit margins and future P/E levels.ICAD: Office Risk Repricing Will Shape Margins And Share Performance
Analysts have lowered their price target on Icade from EUR 25 to EUR 18. This reflects a higher perceived equity risk in offices, alongside slightly faster expected revenue growth but weaker profit margins and a higher valuation multiple.ICAD: Office Weakness And Higher Equity Risk Will Pressure Shares
Analysts have cut their price target on Icade from EUR 17.80 to EUR 14.60, reflecting a lower revenue growth outlook and higher perceived equity risk in offices, even as profit margins are expected to improve. Analyst Commentary Bearish analysts have recently shifted their stance on Icade, highlighting a weaker outlook for office assets and increasing caution around the company’s equity risk profile.
Pulse Building Lease With Seine-Saint-Denis Will Boost Portfolio Strength
Improved rental growth expected from the lease agreement and focus on prime locations may enhance revenue stability.A Look At Icade's (EPA:ICAD) Share Price Returns
Passive investing in an index fund is a good way to ensure your own returns roughly match the overall market. When you...How Did Icade SA's (EPA:ICAD) 8.0% ROE Fare Against The Industry?
One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...What Type Of Shareholders Make Up Icade SA's (EPA:ICAD) Share Registry?
If you want to know who really controls Icade SA ( EPA:ICAD ), then you'll have to look at the makeup of its share...Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2028 | 1,409 | 244 | 111 | 181 | 4 |
| 12/31/2027 | 1,328 | 154 | 831 | 208 | 5 |
| 12/31/2026 | 1,304 | 47 | 962 | 253 | 5 |
| 12/31/2025 | 1,337 | -123 | 300 | 300 | N/A |
| 9/30/2025 | 1,338 | -155 | 314 | 314 | N/A |
| 6/30/2025 | 1,339 | -187 | 328 | 328 | N/A |
| 3/31/2025 | 1,376 | -231 | 347 | 347 | N/A |
| 12/31/2024 | 1,412 | -275 | 366 | 366 | N/A |
| 9/30/2024 | 1,468 | -614 | 316 | 316 | N/A |
| 6/30/2024 | 1,523 | -953 | 265 | 265 | N/A |
| 3/31/2024 | 1,524 | -1,121 | 251 | 251 | N/A |
| 12/31/2023 | 1,525 | -1,289 | 238 | 238 | N/A |
| 9/30/2023 | 1,494 | -1,116 | 317 | 317 | N/A |
| 6/30/2023 | 1,464 | -944 | 397 | 397 | N/A |
| 3/31/2023 | 1,467 | -657 | 319 | 319 | N/A |
| 12/31/2022 | 1,469 | -370 | 242 | 242 | N/A |
| 9/30/2022 | 1,496 | -61 | N/A | N/A | N/A |
| 6/30/2022 | 1,524 | 249 | 547 | 224 | N/A |
| 3/31/2022 | 1,586 | 324 | 538 | 377 | N/A |
| 12/31/2021 | 1,648 | 399 | 529 | 529 | N/A |
| 6/30/2021 | 1,640 | 280 | -51 | 600 | N/A |
| 3/31/2021 | 1,534 | 178 | 34 | 625 | N/A |
| 12/31/2020 | 1,429 | 76 | 120 | 650 | N/A |
| 6/30/2020 | 1,458 | 259 | -233 | 453 | N/A |
| 3/31/2020 | 1,485 | 278 | -325 | 411 | N/A |
| 12/31/2019 | 1,512 | 298 | -417 | 369 | N/A |
| 9/30/2019 | 1,587 | 235 | N/A | 358 | N/A |
| 6/30/2019 | 1,662 | 173 | N/A | 346 | N/A |
| 3/31/2019 | 1,717 | 165 | N/A | 351 | N/A |
| 12/31/2018 | 1,773 | 156 | N/A | 356 | N/A |
| 9/30/2018 | 1,714 | 137 | N/A | 372 | N/A |
| 6/30/2018 | 1,655 | 118 | N/A | 387 | N/A |
| 3/31/2018 | 1,642 | 142 | N/A | 362 | N/A |
| 12/31/2017 | 1,629 | 165 | N/A | 337 | N/A |
| 6/30/2017 | 1,596 | 106 | N/A | 255 | N/A |
| 3/31/2017 | 1,542 | 75 | N/A | 235 | N/A |
| 12/31/2016 | 1,487 | 45 | N/A | 215 | N/A |
| 6/30/2016 | 1,391 | -101 | N/A | 309 | N/A |
| 3/31/2016 | 1,411 | -144 | N/A | 307 | N/A |
| 12/31/2015 | 1,431 | -187 | N/A | 305 | N/A |
| 6/30/2015 | 1,649 | 82 | N/A | 526 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: ICAD wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als schnelleres Wachstum als die Sparquote angesehen wird (2.5%).
Ertrag vs. Markt: ICAD wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als überdurchschnittliches Marktwachstum angesehen wird.
Hohe Wachstumserträge: ICAD wird voraussichtlich in den nächsten 3 Jahren rentabel werden.
Einnahmen vs. Markt: ICADDie Einnahmen des Unternehmens (1.6% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt French (5.6% pro Jahr).
Hohe Wachstumseinnahmen: ICADDie Einnahmen des Unternehmens (1.6% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: ICADDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (5.6%).
Wachstumsunternehmen entdecken
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/05/21 10:02 |
| Aktienkurs zum Tagesende | 2026/05/21 00:00 |
| Gewinne | 2025/12/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Icade wird von 21 Analysten beobachtet. 11 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Celine Huynh | Barclays |
| Paul May | Barclays |
| Celine Huynh | Barclays |